121 related articles for article (PubMed ID: 14519946)
21. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists.
Benbrook DM; Kamelle SA; Guruswamy SB; Lightfoot SA; Rutledge TL; Gould NS; Hannafon BN; Dunn ST; Berlin KD
Invest New Drugs; 2005 Oct; 23(5):417-28. PubMed ID: 16133793
[TBL] [Abstract][Full Text] [Related]
22. Unique anti-activator protein-1 activity of retinoic acid receptor beta.
Lin F; Xiao D; Kolluri SK; Zhang X
Cancer Res; 2000 Jun; 60(12):3271-80. PubMed ID: 10866321
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
24. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma.
Guruswamy S; Lightfoot S; Gold MA; Hassan R; Berlin KD; Ivey RT; Benbrook DM
J Natl Cancer Inst; 2001 Apr; 93(7):516-25. PubMed ID: 11287445
[TBL] [Abstract][Full Text] [Related]
25. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
26. Subacute toxicity of all-trans- and 13-cis-isomers of N-ethyl retinamide, N-2-hydroxyethyl retinamide, and N-4-hydroxyphenyl retinamide.
Sani BP; Meeks RG
Toxicol Appl Pharmacol; 1983 Sep; 70(2):228-35. PubMed ID: 6226123
[TBL] [Abstract][Full Text] [Related]
27. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARgamma independent pathway.
Kitareewan S; Spinella MJ; Allopenna J; Reczek PR; Dmitrovsky E
Oncogene; 1999 Oct; 18(42):5747-55. PubMed ID: 10523855
[TBL] [Abstract][Full Text] [Related]
28. Induction of retinoid resistance in breast cancer cells by overexpression of cJun.
Yang L; Kim HT; Munoz-Medellin D; Reddy P; Brown PH
Cancer Res; 1997 Oct; 57(20):4652-61. PubMed ID: 9377582
[TBL] [Abstract][Full Text] [Related]
29. Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines.
Scher RL; Saito W; Dodge RK; Richtsmeier WJ; Fine RL
Otolaryngol Head Neck Surg; 1998 Apr; 118(4):464-71. PubMed ID: 9560096
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention.
Oridate N; Lotan D; Mitchell MF; Hong WK; Lotan R
J Cell Biochem Suppl; 1995; 23():80-6. PubMed ID: 8747381
[TBL] [Abstract][Full Text] [Related]
31. 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
Anding AL; Jones JD; Newton MA; Curley RW; Clagett-Dame M
Anticancer Res; 2018 Aug; 38(8):4403-4416. PubMed ID: 30061204
[TBL] [Abstract][Full Text] [Related]
32. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide.
Reynolds CP; Wang Y; Melton LJ; Einhorn PA; Slamon DJ; Maurer BJ
Med Pediatr Oncol; 2000 Dec; 35(6):597-602. PubMed ID: 11107126
[TBL] [Abstract][Full Text] [Related]
33. Comparative activity of dietary or topical exposure to three retinoids in the promotion of skin tumor induction in mice.
McCormick DL; Bagg BJ; Hultin TA
Cancer Res; 1987 Nov; 47(22):5989-93. PubMed ID: 2959358
[TBL] [Abstract][Full Text] [Related]
34. Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells.
Appierto V; Villani MG; Cavadini E; Lotan R; Vinson C; Formelli F
Cell Death Differ; 2004 Mar; 11(3):270-9. PubMed ID: 14647238
[TBL] [Abstract][Full Text] [Related]
35. N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
Takahashi N; Sausville EA; Breitman TR
Clin Cancer Res; 1995 Jun; 1(6):637-42. PubMed ID: 9816026
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
Shan D; Gopal AK; Press OW
Clin Cancer Res; 2001 Aug; 7(8):2490-5. PubMed ID: 11489831
[TBL] [Abstract][Full Text] [Related]
37. Retinoid therapy of high-risk neuroblastoma.
Reynolds CP; Matthay KK; Villablanca JG; Maurer BJ
Cancer Lett; 2003 Jul; 197(1-2):185-92. PubMed ID: 12880980
[TBL] [Abstract][Full Text] [Related]
38. Antiproliferative activity and apoptosis induced by retinoic acid receptor-gamma selectively binding retinoids in neuroblastoma.
Meister B; Fink FM; Hittmair A; Marth C; Widschwendter M
Anticancer Res; 1998; 18(3A):1777-86. PubMed ID: 9673404
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line.
Formelli F; Cleris L
Eur J Cancer; 2000 Dec; 36(18):2411-9. PubMed ID: 11094318
[TBL] [Abstract][Full Text] [Related]
40. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
